You have 9 free searches left this month | for more free features.

regorafenib

Showing 26 - 50 of 138

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Colorectal Cancer Trial in Omaha (XL092, Atezolizumab, Regorafenib)

Recruiting
  • Colorectal Cancer
  • Omaha, Nebraska
    Exelixis Clinical Site #1
Jul 26, 2022

Regorafenib, Raltitrexed, Colorectal Tumors Trial (Regorafenib, Raltitrexed)

Not yet recruiting
  • Regorafenib
  • +3 more
  • (no location specified)
Jun 24, 2022

Colorectal Cancer Metastatic Trial in France (Regorafenib)

Recruiting
  • Colorectal Cancer Metastatic
  • Regorafenib
  • Brest, France
  • +11 more
Dec 7, 2022

Metastatic Pancreatic Adenocarcinoma Trial in Cleveland (Regorafenib, Gemcitabine Hydrochloride)

Terminated
  • Metastatic Pancreatic Adenocarcinoma
  • Regorafenib
  • Gemcitabine Hydrochloride
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Jun 1, 2022

Colorectal Cancer, Colorectal Cancer Metastatic Trial in United States (Pembrolizumab, Regorafenib)

Active, not recruiting
  • Colorectal Cancer
  • Colorectal Cancer Metastatic
  • Pembrolizumab
  • Regorafenib
  • Duarte, California
  • +3 more
Aug 5, 2022

Pancreas Cancer, Ovarian Cancer, Melanoma Trial in Rozzano (Regorafenib)

Completed
  • Pancreas Cancer
  • +6 more
  • Regorafenib
  • Rozzano, Milan, Italy
    Istituto Clinico Humanitas
Sep 9, 2022

Colorectal Cancer Trial in Philadelphia (Regorafenib, 5-FU, Leucovorin)

Terminated
  • Colorectal Cancer
  • Regorafenib
  • +2 more
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Jan 10, 2022

Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Kashiwa (Regorafenib,

Not yet recruiting
  • Gastric Adenocarcinoma
  • +2 more
  • Regorafenib
  • +3 more
  • Kashiwa, Chiba, Japan
    National Cancer Center Hospital East
May 23, 2022

Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Regorafenib + sintilimab, Regorafenib)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Regorafenib + sintilimab
  • Regorafenib
  • Guangzhou, Guangdong, China
    the Second Affiliated Hospital of Guangzhou Medical University
Feb 10, 2022

Metastatic Colorectal Cancer Trial in France (other, procedure, drug)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • quality of life questionnaires
  • +6 more
  • Besançon, France
  • +6 more
Jul 15, 2022

Ovarian Cancer, Serous Ovarian Cancer Trial in Pittsburgh (Regorafenib, Fulvestrant)

Not yet recruiting
  • Ovarian Cancer
  • Serous Ovarian Cancer
  • Pittsburgh, Pennsylvania
    University of Pittsburgh Cancer Institute
Apr 17, 2022

Esophagogastric Cancer, HER2-Negative Trial in United States (regorafenib, nivolumab, FOLFOX chemo with oxaliplatin)

Active, not recruiting
  • Esophagogastric Cancer
  • HER2-Negative
  • regorafenib
  • +2 more
  • Basking Ridge, New Jersey
  • +6 more
Nov 23, 2022

Colorectal Tumors Trial in United States (RRx-001, Regorafenib, Irinotecan)

Completed
  • Colorectal Neoplasms
  • La Jolla, California
  • +4 more
May 12, 2022

Adenoid Cystic Carcinoma Trial in United States (Regorafenib)

Active, not recruiting
  • Adenoid Cystic Carcinoma
  • Regorafenib
  • Basking Ridge, New Jersey
  • +4 more
Apr 26, 2022

Thyroid Cancer Trial in New Haven, Boston (Regorafenib)

Recruiting
  • Thyroid Cancer
  • Regorafenib
  • New Haven, Connecticut
  • +1 more
Feb 18, 2022

Stage IB Hepatocellular Carcinoma AJCC v8, Stage II Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC

Not yet recruiting
  • Stage IB Hepatocellular Carcinoma AJCC v8
  • +2 more
  • Durvalumab
  • Regorafenib
  • Gainesville, Florida
  • +3 more
Jun 15, 2022

Advanced Biliary Tract Cancer Trial in United States (Durvalumab, Regorafenib)

Recruiting
  • Advanced Biliary Tract Cancer
  • Overland Park, Kansas
  • +4 more
May 17, 2022

Adult Angiosarcoma, Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma Trial in United States

Completed
  • Adult Angiosarcoma
  • +3 more
  • regorafenib
  • Santa Monica, California
  • +6 more
Mar 29, 2022

Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma Trial in United States (Regorafenib, Placebo)

Completed
  • Liposarcoma
  • +4 more
  • Regorafenib
  • Placebo
  • Duarte, California
  • +17 more
Oct 25, 2022

Glioblastoma Multiforme Trial in Italy (Regorafenib, Lomustine)

Active, not recruiting
  • Glioblastoma Multiforme
  • Castellana Grotte, BA, Italy
  • +9 more
Mar 31, 2022

Rectal Cancer Trial in Switzerland (drug, radiation, procedure)

Terminated
  • Rectal Cancer
  • Regorafenib
  • +3 more
  • Basel, Switzerland
  • +6 more
Jan 14, 2022

KRAS Gene Mutation, Metastatic Malignant Tumor in the Brain, Recurrent Non-Small Cell Lung Carcinoma Trial in Palo Alto

Active, not recruiting
  • KRAS Gene Mutation
  • +3 more
  • Palo Alto, California
    Stanford University School of Medicine
Feb 9, 2022

Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • iNKT Cells
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jul 24, 2023

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1

Not yet recruiting
  • HCC
  • +3 more
  • Regorafenib
  • cTACE/DEB-TACE-HAIC
  • (no location specified)
Aug 28, 2021

Cancer of the Bile Duct Trial in Tampa, Chapel Hill, Richmond (Regorafenib)

Completed
  • Cancer of the Bile Duct
  • Regorafenib
  • Tampa, Florida
  • +2 more
Sep 20, 2021